Song David, Shabani Jawad, Jaiswal Vikash, Paudel Kusum, Gupta Arjun, Rubinstein David
Department of Internal Medicine Icahn School of Medicine at Mount Sinai - Elmhurst Hospital Center New York City New York USA.
Department of Cardiovascular Research Larkin Community Hospital Miami Florida USA.
Clin Case Rep. 2023 Apr 23;11(4):e7246. doi: 10.1002/ccr3.7246. eCollection 2023 Apr.
Pericardial effusion leading to cardiac tamponade can occur due to a multitude of etiologies, one of which is medication adverse effects. In patients with comorbid conditions, this can prove to be a challenge in its co-management along with the primary disease. We present a rare case of anagrelide-induced pericardial effusion that is presented with tamponade physiology in a patient with essential thrombocythemia. After cautiously weighing the risks and benefits of further invasive interventions following an unsuccessful pericardiocentesis, the decision was to stop anagrelide while managing the pericardial effusion medically. Therefore, managing pericardial effusion should be tailored to each patient individually through shared decision-making.
心包积液导致心脏压塞可由多种病因引起，其中之一是药物不良反应。在患有合并症的患者中，这可能被证明是在与原发性疾病共同管理方面的一项挑战。我们报告一例罕见的因使用阿那格雷引起的心包积液病例，该患者患有原发性血小板增多症，并出现了心脏压塞生理学表现。在心包穿刺术失败后，谨慎权衡进一步侵入性干预措施的风险和益处后，决定停用阿那格雷，同时对心包积液进行药物治疗。因此，应通过共同决策为每位患者量身定制心包积液的管理方案。
